Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, Catalyst Pharmaceuticals Inc’s stock clocked out at $19.13, down -2.89% from its previous closing price of $19.7. In other words, the price has decreased by -$2.89 from its previous closing price. On the day, 1.06 million shares were traded. CPRX stock price reached its highest trading level at $19.71 during the session, while it also had its lowest trading level at $19.05.
Ratios:
To gain a deeper understanding of CPRX’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 3.59 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 8.52. For the most recent quarter (mrq), Quick Ratio is recorded 6.55 and its Current Ratio is at 6.71. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Robert W. Baird on February 04, 2025, initiated with a Outperform rating and assigned the stock a target price of $28.
On November 18, 2024, Stephens started tracking the stock assigning a Overweight rating and target price of $35.
On March 14, 2024, Citigroup started tracking the stock assigning a Buy rating and target price of $27.Citigroup initiated its Buy rating on March 14, 2024, with a $27 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Sep 08 ’25 when Elsbernd Brian sold 30,000 shares for $20.30 per share. The transaction valued at 609,000 led to the insider holds 271,039 shares of the business.
Elsbernd Brian bought 30,000 shares of CPRX for $609,035 on Sep 08 ’25. On Sep 04 ’25, another insider, Elsbernd Brian, who serves as the Chief Compliance/Legal Officer of the company, sold 30,000 shares for $19.52 each. As a result, the insider received 585,600 and left with 188,564 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CPRX now has a Market Capitalization of 2411102976 and an Enterprise Value of 1691531008. As of this moment, Catalyst’s Price-to-Earnings (P/E) ratio for their current fiscal year is 11.61, and their Forward P/E ratio for the next fiscal year is 11.15. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.03. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.19 while its Price-to-Book (P/B) ratio in mrq is 2.74. Its current Enterprise Value per Revenue stands at 3.029 whereas that against EBITDA is 6.014.
Stock Price History:
The Beta on a monthly basis for CPRX is 0.80, which has changed by -0.021983624 over the last 52 weeks, in comparison to a change of 0.15101504 over the same period for the S&P500. Over the past 52 weeks, CPRX has reached a high of $26.58, while it has fallen to a 52-week low of $19.15. The 50-Day Moving Average of the stock is -6.46%, while the 200-Day Moving Average is calculated to be -13.81%.
Shares Statistics:
It appears that CPRX traded 1.49M shares on average per day over the past three months and 1546120 shares per day over the past ten days. A total of 122.39M shares are outstanding, with a floating share count of 111.42M. Insiders hold about 8.96% of the company’s shares, while institutions hold 81.22% stake in the company. Shares short for CPRX as of 1756425600 were 7927886 with a Short Ratio of 5.81, compared to 1753920000 on 9225801. Therefore, it implies a Short% of Shares Outstanding of 7927886 and a Short% of Float of 8.28.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 4.0 analysts currently analyzing and rating the stock of Catalyst Pharmaceuticals Inc (CPRX).The consensus estimate for the next quarter is $0.45, with high estimates of $0.54 and low estimates of $0.27.
Analysts are recommending an EPS of between $2.51 and $2.08 for the fiscal current year, implying an average EPS of $2.34. EPS for the following year is $2.51, with 4.0 analysts recommending between $2.69 and $2.37.
Revenue Estimates
In the current quarter, 7 analysts expect revenue to total $136.77M. It ranges from a high estimate of $143.01M to a low estimate of $132M. As of the current estimate, Catalyst Pharmaceuticals Inc’s year-ago sales were $128.69MFor the next quarter, 7 analysts are estimating revenue of $136.95M. There is a high estimate of $140.78M for the next quarter, whereas the lowest estimate is $133.11M.
A total of 7 analysts have provided revenue estimates for CPRX’s current fiscal year. The highest revenue estimate was $571.78M, while the lowest revenue estimate was $556.1M, resulting in an average revenue estimate of $561.71M. In the same quarter a year ago, actual revenue was $491.73MBased on 7 analysts’ estimates, the company’s revenue will be $615.52M in the next fiscal year. The high estimate is $637.7M and the low estimate is $570.37M.
